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Purpose: To estimate cure rate following graft rejection in bilateral corneal transplants 
in Iranian patients with keratoconus and to determine risk factors associated with 
rejection.
Methods: In this retrospective study, data were compiled from records of patients 
who had undergone bilateral penetrating keratoplasty (PK) for keratoconus between 
1988 and 2007. In order to estimate cure rate in patients with and without corneal 
vascularization, we adopted the cure rate frailty model with a Bayesian approach.
Results: Two hundred and thirty-eight eyes of 119 patients underwent bilateral 
corneal transplantion for keratoconus, of which 22.7% experienced graft rejections. 
Cure rates for patients with and without corneal vascularization were 41% and 79%, 
respectively. Cure rate decreased 12% per decade of increase in recipient age. The 1, 
5, and 10-year survival of corneal transplants without any graft rejection episodes 
were 82%, 74%, and 70% respectively.
Conclusion: The most important risk factor predisposing to rejection in patients 
undergoing bilateral PK for keratoconus was corneal vascularization. Cure rate for 
patients without vascularization was high in this data set, indicating that penetrating 
keratoplasty in keratoconus patients without vascularization is an efficient and 
reliable procedure.
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INTRODuCTION
Corneal transplantation aims to replace abnormal 
corneas with normal tissue. Keratoconus is one 
of the most common indications for corneal 
transplantation, accounting for 11% to 31% of 
cases of penetrating keratoplasty (PK).1-5 In 
Iran, a total of 19,668 corneal transplants were 
performed between 1994 and 2004, of which, 
34.5% were for keratoconus.6
Keratoconus  is  a  progressive,  non-
inflammatory, bilateral, but asymmetrical 
disease in which the cornea bulges and takes 
an irregular conical shape instead of the 
normal spherical shape, resulting in myopia 
and irregular astigmatism and hence, poor 
vision.7-9 In advanced cases where contact lenses 
and intracorneal rings are inappropriate or not 
sufficient to correct vision or when contact 
lens intolerance develops, corneal transplant 
surgery may become necessary.
Keratoconus is one of the most common 
indications for corneal transplant procedures 
with a favorable outcome.10-13 However, graft Cure Rate after Graft Rejection; Rahimzadeh et al
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failure is possible, the major cause of which is 
graft rejection.14-17 Approximately 6,000 corneal 
transplant procedures are performed each year 
around the world, one-third of which become 
complicated by graft rejection reactions at least 
once ultimately leading to graft failure in 5% 
to 7% of cases.18-20 Various studies around 
the world have reported different rates of 
rejection. Possible reasons for this discrepancy 
are diversity in definitions for graft rejection 
reactions, different durations of follow-up and 
various indications for transplantation.18
This study was designed to determine 
risk factors for graft rejection in keratoconus 
patients who had undergone bilateral PK. In 
keratoconus patients, the more severely affected 
eye is usually considered for keratoplasty, 
while the other is managed conservatively 
using spectacles or rigid gas-permeable contact 
lenses. In cases requiring bilateral keratoplasty, 
the second operation is postponed until all 
sutures are removed from the operated eye. 
We considered a corneal graft as rejected when 
it remained clear for at least 10 to 14 days 
following surgery and then started showing 
signs of rejection due to recipient immune 
response.
There  are  some  known  risk  factors 
predisposing to corneal graft rejection, including 
the genetic composition of the host which is 
the same for fellow eyes in bilateral cases and 
may cause a correlation in the survival of 
bilateral grafts. Due to such immeasurable risk 
factors, utilizing the Cox proportional hazard 
model21 produces biased results.22 This issue 
can be addressed by multiplying a random 
effect with the hazard function. In the context 
of survival analysis, this random effect is 
referred to as the frailty effect and the adopted 
model is called the Cox frailty model.23-25 In 
the case of bilateral corneal transplantations, 
it is clear that data from the two eyes cannot 
be considered to be independent. The frailty 
model explicitly formulates the nature of the 
underlying dependence structure.26
To assess the goodness of fit of the models, 
the Deviance Information Criteria (DIC) was 
employed, as a result of which the smallest 
value shows better fitness of the model.27
METHODS
Among organ transplantations, corneal 
transplantation has the most favorable 
prognosis with a clear graft survival rate 
exceeding 90% over a 5-year period.28 From a 
statistical point of view, these individuals are 
considered “cured” or immune and are not at 
risk for event occurrence. Although clinical 
observations indicate that graft rejection can 
occur even several decades after transplantation, 
the probability of graft rejection will be very 
small with such long-term follow up. In such 
situations, the population is divided into two 
groups. The first group consists of individuals 
who with adequate follow-up will eventually 
experience the event of interest, whereas the 
second group comprises individuals who are 
immune to the occurrence of the event. In 
medical studies that concern a proportion of 
individuals who are immune to the event of 
interest, analyzing data using cure models 
has been considered. For the first time, cure 
models were introduced in 1949 by Boag29 and 
later improved by Chen et al30 in 1999 using 
a Bayesian approach. Given the bilaterality 
of corneal transplantations, low risk of graft 
rejection, and the presence of unidentified 
risk factors influencing survival periods, we 
used a cure rate frailty model with a Bayesian 
approach31 to assess factors associated with 
rejection of bilateral corneal grafts.
In this retrospective analytic case series, 
records of 119 keratoconus patients who had 
undergone bilateral corneal transplantation 
at Labbafinejad Medical Center, Tehran, Iran 
between 1988 and 2007 were compiled. Graft 
survival period was considered the time interval 
between corneal transplant surgery and the onset 
of an episode of graft rejection reaction. If the 
eye did not experience any rejection episodes, the 
time interval between corneal transplantation 
and last examination was defined as censored 
survival time. Collected data included: date of 
surgery, date of the first rejection episode, date 
of final eye examination, and status of graft 
rejection. Recipient information included sex, 
age at the time of surgery, presence of severe 
eye allergies and vascularization of the cornea. Cure Rate after Graft Rejection; Rahimzadeh et al
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Donor information included time interval 
from tissue harvesting to transplantation. If a 
survival function curve by the Kaplan-Meier 
method leveled out before reaching the zero 
point, it was concluded that the risk of ongoing 
rejection episodes was low.
Some patients with bilateral corneal 
grafts are not at risk of failure, and there is 
heterogeneity among survival times, in order to 
account for these problems, the cure rate frailty 
model with a Bayesian approach by Yin31 was 
applied for the estimation of the prognostic 
factors of corneal graft rejection.
Since piecewise exponential models are 
flexible and fit well in the hazard function of 
any type of data, this function was used. In 
addition, the log-normal probability distribution 
function was utilized for frailty distribution.
RESuLTS
Overall 238 eyes of 119 subjects with keratoconus 
underwent bilateral PK and were followed for 
a mean of 43.9 months (range, 1-221 months). 
During the follow-up period, 54 patients (22.7%) 
experienced first graft rejections, 31 of which 
involved the first eye and the rest happened 
in the second eye. Overall, 18 cases of corneal 
graft rejections were bilateral (9 patients) and 
36 cases were unilateral. Rejection episodes 
occurred 1.1 to 95 months postoperatively with 
a mean and median of 12.5 and 6.9 months, 
respectively. Rejection occurred in 20.8% and 
58.3% of patients without and with corneal 
vascularization, respectively. No statistically 
significant difference was found between graft 
survival in first and second eyes using the Log 
rank test (p=0.9). Based on the estimation of 
parameters in the cure frailty model, patient 
age and presence of corneal vascularization 
had a significant negative correlation with 
cure rate (P < 0.05; table 1). The 1, 5, and 10-
year rejection-free survival rates of corneal 
transplants in this study were 82%, 74%, and 
70%, respectively (Fig. 1).
Given that rejection episodes are most 
likely to occur in the first 18 months following 
surgery, a small or moderate number of intervals 
is recommended in cure models.32 We divided 
the follow-up period into two time spans of 0 
to 18 months, and 18 to 221 months to estimate 
piecewise exponential hazard functions which 
revealed that the risk of graft rejection in the 
first time span is 6 times higher than that in the 
second time span, resembling other studies.33 
Using more intervals, we observed that the 
DIC increased (table 2).
The frailty effect variance > 0 indicates the 
presence of other unknown risk factors which 
cannot be addressed using available covariates. 
In the cure model, cure rate with and without 
vascularization for example is calculated using 
the following formula: exp (-exp (intercept + beta 
P-value SD Mean Parameter
0.0001 0.297 -1.45 Intercept
0.01 0.017 0.05 Age
0.00001 1.067 1.34 Vascularization
0.001 0.012 0.064 Lambda 1*
0.005 0.01 0.016 Lambda 2*
0.001 0.68 1.8 Frailty
Table 1.  Parameter  estimation  in  the  cure  rate  frailty 
model
SD, standard deviation
*parameter of piecewise distribution
Interval (months)
(0,18] (18,221]
(0,6]  (6,18]  
(18,60] (60,221]
Cox Frailty Model 449.19 452.36
Cure Frailty Model 431.51 435.68
Table 2.  Model  selection  criteria  based  on  DIC  with 
respect to time spans
DIC, deviance information criteria
Figure 1. Kaplan Meier survival curves based on first 
and second grafts.Cure Rate after Graft Rejection; Rahimzadeh et al
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× parameter)). Thus, using the cure rate frailty 
model in this study, cure rate was estimated 
to be 41% for patients with vascularization 
and 79% for patients without vascularization 
(Fig. 2). Cure rate was reduced by 12% per 
decade of increase in recipient age.
We used the Cox frailty model that 
assumes all subjects will experience the event 
if follow-up is extended (results not shown). 
The DIC determined both models and its 
smallest value showed better fit for cure frailty 
models. Therefore, the cure or immunity rate 
is significant in this data set (table 2).
In cases with repeat transplantations, the 
time interval between the first and second graft 
was 3.8 to 204 months with a mean of 44.6 
months. This period was less than a year in 7% 
of cases who underwent regrafts. In order to 
assess the effect of time interval between the two 
transplant surgeries, we used the cure model 
and incorporated time interval into the model 
as an influencing factor. Based on this model, 
cure rate for the second eye was significantly 
reduced by decreasing the time interval from 
the first to second transplants (P=0.01).
DISCuSSION
Identification of risk factors affecting cure rates 
and estimation of rejection-free survival rates 
in subgroups of corneal transplant patients are 
of great importance. Corneal transplantation is 
one of the most successful organ transplantation 
procedures. However, corneal graft rejection is 
relatively common and is the leading cause of 
corneal graft failure, resulting in graft failure in 
30% to 40% of patients.34 In this study, recipient 
corneal vascularization and advanced recipient 
age were found as risk factors influencing 
cure rate. Rejection occurred in 20.8% and 
58.3% of the patients without and with corneal 
vascularization, respectively. A study by 
Khodadoust and Karnema35 revealed a rejection 
rate of 7.5% and 39% in non-vascularized and 
vascularized corneas, respectively (P<0.05).
During the follow-up period, rejection 
occurred in 22.7% of subjects in the present 
study which is comparable to the rate (26.6%) 
reported by Sinha et al36. The rate of graft 
rejection was 26.1% and 19.3% for first and 
second eyes, respectively and exceeds the 
rates (11% and 8%) reported by Rao et al.37 
The higher rejection rate for the first eye as 
compared to that for the second eye can be 
attributed to the longer follow-up period. 
However, the difference between the two eyes 
did not reach a significant level in either of the 
studies. This observation is in line with the 
results of Ozbek et al.38
Different studies report varying outcomes 
after bilateral corneal grafts. In this study, 
decreasing the time interval between the first 
and second transplants resulted in reduction of 
cure rate. Buxton et al39 noted that performing 
a corneal transplant on the second eye is a 
risk factor for graft rejection in the first eye, 
whereas in the study carried out by Donshik 
et al40 a corneal graft in the second eye did not 
impose any threat to the first.
Using multivariate analysis of data obtained 
from bilateral corneal transplants, we assessed 
factors influencing cure rate. In this study, 
graft survival durations were considered as 
parallel variables. However, this is not the 
case in reality and it must be noted that the 
transplant on the second eye was performed 
after a period of time following transplantation 
in the first eye. Additionally, this study is 
retrospective, therefore, it is not possible to 
systematically review all risk factors such as 
loose sutures and previous ocular surgery as 
Figure 2.  Kaplan  Meier  survival  curves  based  on  the 
presence or absence of vascularization.Cure Rate after Graft Rejection; Rahimzadeh et al
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some data were missing and certain patients 
were lost to follow-up.
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